Well, that would help ... each patent year is calculable with "favorable" revenues, for future value projections. Which is a strong negotiating point.
I don't mind the cancer crossover potential with Zenith either. Since Zenith is hot on that trail, one more possible way to get dragged along in a good thing for Zenith potentially, or at least make sense for mutual/added interests.